Oncolys BioPharma, Inc. (4588) Stock Statistics & Valuation Metrics

Oncolys BioPharma, Inc. has a market cap or net worth of ¥71.68B. The enterprise value is ¥51.68B.

Oncolys BioPharma, Inc. has 29,291,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oncolys BioPharma, Inc.’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -46.76%.

The current PE Ratio of Oncolys BioPharma, Inc. is ―. Oncolys BioPharma, Inc.’s PEG ratio is -4.72.

In the last 12 months, Oncolys BioPharma, Inc. had revenue of 28.55M and earned -2.06B in profits. Earnings per share was -80.00.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Oncolys BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Oncolys BioPharma, Inc. upcoming earnings date is May 8, 2026, TBA (Confirmed).

Oncolys BioPharma, Inc. as a current ratio of 9.55, with Debt / Equity ratio of 8.00%

In the past 12 months, Oncolys BioPharma, Inc. has paid 4.03M in taxes.

Oncolys BioPharma, Inc. EV to EBITDA ratio is -15.74, with an EV/FCF ratio of -16.59.

Oncolys BioPharma, Inc. has ¥1.39B in cash and marketable securities with ¥377.04M in debt, giving a net cash position of ¥1.01B billion.

Gross margin is 99.15%, with operating margin of -7090.55%, and net profit margin of -7209.59%.

The average price target for Oncolys BioPharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―